ArticleMolecules (Basel, Switzerland)2026
Cannabigerol Modulates Blood Pressure and Vascular Reactivity in a Rat Model of Hypertension and Platelet Responses in Human Blood In Vitro.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cannabigerol (CBG) exerts vasorelaxant effects in human pulmonary arteries and lowers blood pressure (BP) in normotensive mice. However, data on the cardiovascular effects of CBG in hypertension and platelet function remain limited. Consequently, the aims of our study were as follows: to assess the effect of CBG on BP and heart rate (HR) in spontaneously hypertensive rats (SHR) and their normotensive controls (Wistar Kyoto rats; WKY); to investigate the vasorelaxant potential of CBG in small mesenteric arteries (sMAs) and the aorta; and to investigate the effect of CBG on platelet function in human blood. Acute CBG administration (1, 3, and 10 mg/kg) dose-dependently lowered BP and HR in SHR and WKY rats, with comparable effects between strains (except for a greater reduction in systolic BP in SHR). Furthermore, experiments on pithed rats support the possibility of both central and peripheral contributions to this hypotensive effect. The peripheral component is supported by CBG-induced vasorelaxation in sMAs and aortas, which was more pronounced in sMAs and in WKY rats. Additionally, we demonstrated that CBG inhibits platelet aggregation (collagen-induced) and secretion and reduces thrombus formation and platelet procoagulant response under arterial flow conditions. Taken together, these data indicate that CBG exerts multifaceted cardiovascular effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.